BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 171 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,622,120 | +22.2% | 971,639 | -20.3% | 3.94% | +34.9% |
| Q2 2023 | $20,970,240 | -12.1% | 1,219,200 | -15.2% | 2.92% | -15.0% |
| Q1 2023 | $23,844,693 | +235.1% | 1,438,160 | +54.0% | 3.43% | +209.7% |
| Q4 2022 | $7,115,122 | -23.3% | 933,743 | 0.0% | 1.11% | -30.8% |
| Q3 2022 | $9,281,000 | +9.5% | 933,743 | 0.0% | 1.60% | -29.2% |
| Q2 2022 | $8,478,000 | -63.2% | 933,743 | -58.8% | 2.26% | -54.5% |
| Q1 2022 | $23,015,000 | -21.9% | 2,267,486 | +28.3% | 4.98% | -13.3% |
| Q4 2021 | $29,482,000 | +10.5% | 1,767,486 | +210.4% | 5.74% | -12.7% |
| Q3 2021 | $26,688,000 | +14.9% | 569,414 | +49.5% | 6.57% | +36.6% |
| Q2 2021 | $23,221,000 | – | 380,928 | – | 4.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |